ARTICLE
|
doi:10.20944/preprints202409.0812.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Non-small cell lung cancer; Nivolumab; older patients
Online: 10 September 2024 (13:12:21 CEST)
ARTICLE
|
doi:10.20944/preprints202310.1204.v1
Subject:
Medicine And Pharmacology,
Other
Keywords:
gastric cancer; Nivolumab; immune response; tumor microenvironment; RNA-Seq
Online: 19 October 2023 (03:29:48 CEST)
ARTICLE
|
doi:10.20944/preprints202306.1491.v1
Subject:
Medicine And Pharmacology,
Gastroenterology And Hepatology
Keywords:
epithelial–mesenchymal transition (EMT); Gastric cancer; lipopolysaccharides (LPS); Nivolumab; TGF-β
Online: 21 June 2023 (07:28:13 CEST)
ARTICLE
|
doi:10.20944/preprints201809.0591.v1
Subject:
Medicine And Pharmacology,
Neuroscience And Neurology
Keywords:
adverse events; immune checkpoint inhibitor; myasthenia gravis; myopathy; neuropathy; nivolumab; pembrolizumab
Online: 29 September 2018 (11:28:00 CEST)
REVIEW
|
doi:10.20944/preprints202108.0037.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
ovarian cancer; checkpoint inhibitors; ICIs; immunotherapy; PARP; avelumab; pembrolizumab; nivolumab; bevacizumab; platinum
Online: 2 August 2021 (13:01:35 CEST)
REVIEW
|
doi:10.20944/preprints201909.0140.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
hepatocellular carcinoma; immune checkpoint inhibitors; HCC; pembrolizumab; nivolumab; immune microenvironment; targeted therapies
Online: 14 September 2019 (18:37:29 CEST)
ARTICLE
|
doi:10.20944/preprints202406.1840.v1
Subject:
Medicine And Pharmacology,
Otolaryngology
Keywords:
recurrent/metastatic head and neck squamous cell carcinoma; nivolumab; long-term responder; active treatment discontinuation; timing
Online: 26 June 2024 (10:47:37 CEST)
ARTICLE
|
doi:10.20944/preprints202111.0447.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immunotherapy; immune-checkpoint inhibitor; response prediction; men and women; pembrolizumab; nivolumab; atezolizumab; ECOG; CRP; chemo-immunotherapy
Online: 24 November 2021 (09:02:46 CET)
REVIEW
|
doi:10.20944/preprints202307.0430.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
Hodgkin lymphoma; relapsed/refractory; brentuximab vedotin; checkpoint inhibitor; PD-1 inhibitor; nivolumab; pembrolizumab; autologous hematopoietic cell transplantation
Online: 6 July 2023 (11:44:13 CEST)
ARTICLE
|
doi:10.20944/preprints202305.0561.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Nivolumab; immunotherapy; head and neck cancers; HNSCC; chemotherapy; neutrophil to lymphocyt ratio; NLR; second primary malignancy; Cetuximab
Online: 9 May 2023 (04:21:38 CEST)
ARTICLE
|
doi:10.20944/preprints201811.0609.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
immune checkpoint inhibitors; immune-related adverse events (irAEs); tolerance; ipilimumab; nivolumab; interleukin-2; hyperthermia; low-dose-combination therapy
Online: 28 November 2018 (10:23:31 CET)
ARTICLE
|
doi:10.20944/preprints201808.0307.v3
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immune Checkpoint Inhibitors; anti-PD-1/PDL-1; anti-CTLA-4; gender; sex; Nivolumab; Pembrolizumab; Atezolizumab; Ipilimumab; Durvalumab
Online: 15 November 2018 (07:02:24 CET)
ARTICLE
|
doi:10.20944/preprints202311.0688.v1
Subject:
Biology And Life Sciences,
Biochemistry And Molecular Biology
Keywords:
melanoma; metastasis; overall survival; progression-free survival; side effects; Nivolumab; Ipilimumab; anti-programmed death-1 antibodies; anti-cytotoxic T-lymphocyte antigen-4 antibodies.
Online: 10 November 2023 (11:05:56 CET)